Researchers Studied Multi-Cancer Blood Test
The GRAIL Galleri test is being evaluated for its ability to detect 50 different types of cancer.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Would you choose to use a multi-cancer early detection blood test if it were available?
Scientists at the OHSU Knight Cancer Institute have been investigating a multi-cancer early detection blood test. The study evaluates the GRAIL Galleri test, which aims to identify 50 types of cancer by detecting DNA shed into the bloodstream.
Why it matters
This research addresses a significant gap in healthcare, as standard screening protocols currently identify only 14 percent of cancers. Most cancers are only discovered after they become symptomatic or are found incidentally during unrelated medical visits.
The clinical trial includes 35,000 adults aged 50 and older from the U.S. and Canada. The GRAIL Galleri test is designed to screen for 50 types of cancer, a significant increase over the 14 percent currently captured by standard screenings.
The players
OHSU Knight Cancer Institute
This facility is a cancer research center based in Portland, Oregon, that conducts clinical studies.
GRAIL
This healthcare company developed the Galleri test designed to detect multiple cancer types from a blood draw.
The details
The blood test works by identifying unique DNA shed by cancerous cells into a patient's bloodstream. When the test detects a positive result, it provides an indication of a specific body region to help doctors prioritize targeted diagnostic procedures.
Timeline
October 6, 2026: Researchers reported on the progress of the blood test study.
The Big Picture
This study follows the established pattern of the OHSU Knight Cancer Institute research program in pioneering new diagnostic technologies.
If validated, this blood test could shift the standard of care by allowing for earlier detection of cancers that currently lack conventional screening methods. Patients may eventually use these tests to identify potential malignancies before symptoms manifest.
The takeaway
Early detection technologies represent a major transition toward proactive oncology rather than reactive treatment. Residents should continue following current medical guidelines until new screening methods are officially recommended for routine use.
Further reading
Learn more about the latest innovations in oncology at the Cancer section.
Source note: This article includes information reported by KOBI-TV NBC5 / KOTI-TV NBC2.
Live Poll
Would you choose to use a multi-cancer early detection blood test if it were available?
